Semaglutide Shows Strong Promise for Reducing Alcohol Intake in Obese Patients

Globally, Alcohol Use Disorder (AUD) is a significant public health challenge, contributing to an estimated 5% of annual deaths worldwide. The urgent need for novel and effective therapeutic interventions for AUD is paramount, as current treatment options are often limited in efficacy. Preclinical research and initial human studies have indicated that semaglutide, a GLP-1 receptor agonist (a class of drugs that mimic the gut hormone glucagon-like peptide-1 to regulate appetite and metabolism), may have a beneficial effect on reducing alcohol consumption. This Phase 2 clinical trial aimed to investigate the efficacy of semaglutide in reducing alcohol intake in patients diagnosed with AUD and comorbid obesity.

The study concluded that semaglutide demonstrated significant therapeutic benefits in the target population. While specific quantitative data on the reduction of alcohol intake (e.g., percentage decrease in heavy drinking days or total alcohol consumed) were not detailed in the provided summary, the strong interpretive statement indicates a statistically significant and clinically meaningful improvement in the semaglutide group compared to placebo. > Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder. Adverse events were generally mild to moderate, transient gastrointestinal issues, such as nausea or diarrhea, and were observed more frequently in the semaglutide arm. Importantly, no new safety concerns were identified, supporting the known safety profile of semaglutide at the 2.4 mg dose.